Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04473664 · ClinicalTrials.gov registry record · Phase 1
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04473664 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 12 participants.
The verdict
NCT04473664, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of Feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3). Quizartinib is currently being studied alone or in combination with other agents as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in adult and pediatric populations.
Interventions
- DRUG Quizartinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2021-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04473664
The ClinicalTrials.gov registry entry for NCT04473664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quizartinib is the first listed.
NCT04473664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04473664 about?
NCT04473664 is a clinical study titled "A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment". Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of Feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3). Quizartinib is currently being studied alone or in combination with other agents as a treat...
What is the current status of trial NCT04473664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-09-22. Estimated completion is 2021-07-22.
What interventions are being tested in trial NCT04473664?
The interventions under investigation include: Quizartinib (DRUG).
Who is sponsoring clinical trial NCT04473664?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.